Proteomes behind diverse COVID-19 serology

1	Proteomics Investigation of Diverse Serological Patterns in COVID-19
2	
3	Xiao Liang <sup>1,2,3,4</sup> , Rui Sun <sup>2,3,4</sup> , Jing Wang <sup>5</sup> , Kai Zhou <sup>5</sup> , Jun Li <sup>5</sup> , Shiyong Chen <sup>5</sup> , Mengge Lyu <sup>2,3,4</sup> ,
4	Sainan Li <sup>2,3,4</sup> , Zhangzhi Xue <sup>2,3,4</sup> , Yingqiu Shi <sup>2,3,4</sup> , Yuting Xie <sup>2,3,4</sup> , Qiushi Zhang <sup>6</sup> , Xiao Yi <sup>6</sup> , Juan
5	Pan <sup>5</sup> , Donglian Wang <sup>5</sup> , Jiaqin Xu <sup>5</sup> , Hongguo Zhu <sup>5</sup> , Guangjun Zhu <sup>5</sup> , Jiansheng Zhu <sup>5</sup> , Yi Zhu <sup>2,3,4,6</sup> ,
6	Yufen Zheng <sup>5*</sup> , Bo Shen <sup>5*</sup> , Tiannan Guo <sup>1,2,3,4*</sup>
7	
8	<sup>1</sup> Fudan University, Shanghai, China;
9	<sup>2</sup> Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake
10	University, Hangzhou, Zhejiang, China;
11	<sup>3</sup> Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine,
12	Hangzhou, Zhejiang, China;
13	<sup>4</sup> Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang,
14	China;
15	<sup>5</sup> Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai,
16	Zhejiang, China;
17	<sup>6</sup> Westlake Omics (Hangzhou) Biotechnology Co., Ltd., Hangzhou, Zhejiang, China.
18	* Corresponding authors
19	
20	Correspondence: Y.Z (zhengyf@enzemed.com), B.S (shenb@enzemed.com), and T.G
21	(guotiannan@westlake.edu.cn)
22	
23	Running title: Proteomes behind diverse COVID-19 serology
24	Keywords: COVID-19; serology; proteomics; inflammation; cellular immunity.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Proteomes behind diverse COVID-19 serology

#### 25 Abbreviations

- ADE, antibody-dependent enhancement; ARDS, acute respiratory distress syndrome; C1, 26
- 27 complement 1; CLIA, chemiluminescence immunoassay; COVID-19, Coronavirus Disease 2019;
- 28 CV, coefficient of variation; DDA, data-dependent acquisition; DEP, differentially expressed
- 29 protein; EHR, electronic hospital record; HDL-C, high-density lipoprotein cholesterol; IQR,
- 30 interquartile range; LDL-C, low-density lipoprotein cholesterol; LOESS, locally weighted
- 31 scatterplot smoothing NAb, neutralizing antibody; nonVac, non-vaccinated; PCA, principal
- 32 component analysis; R1, one-year revisit; R2, two-year revisit; RBD, receptor binding domain;
- 33 RLU, relative luminescence unit; RT-PCR, reverse-transcriptase polymerase-chain-reaction; TC,
- 34 total cholesterol; TEAB, triethylammonium bicarbonate; TG, triglyceride; TMT, tandem mass tag;
- 35 Vac, vaccinated.

36

#### 37 Abstract

38 Serum antibodies IgM and IgG are elevated during COVID-19 to defend against viral attack. 39 Atypical results such as negative and abnormally high antibody expression were frequently 40 observed whereas the underlying molecular mechanisms are elusive. In our cohort of 144 COVID-41 19 patients, 3.5% were both IgM and IgG negative whereas 29.2% remained only IgM negative. 42 The remaining patients exhibited positive IgM and IgG expression, with 9.3% of them exhibiting 43 over 20-fold higher titers of IgM than the others at their plateau. IgG titers in all of them were 44 significantly boosted after vaccination in the second year. To investigate the underlying molecular 45 mechanisms, we classed the patients into four groups with diverse serological patterns and 46 analyzed their two-year clinical indicators. Additionally, we collected 111 serum samples for 47 TMTpro-based longitudinal proteomic profiling and characterized 1494 proteins in total. We 48 found that the continuously negative IgM and IgG expression during COVID-19 were associated 49 with mild inflammatory reactions and high T cell responses. Low levels of serum IgD, inferior 50 complement 1 activation of complement cascades, and insufficient cellular immune responses might collectively lead to compensatory serological responses, causing overexpression of IgM. 51 52 Serum CD163 was positively correlated with antibody titers during seroconversion. This study

Proteomes behind diverse COVID-19 serology

53 suggests that patients with negative serology still developed cellular immunity for viral defense,

54 and that high titers of IgM might not be favorable to COVID-19 recovery.

55

# Introduction 56

57 COVID-19 remains a threat to global health. The production of serum antibodies in the 58 human body is a major defensive mechanism to neutralize SARS-CoV-2. Within them, IgM is 59 initiated during the acute phase for early defense whereas IgG is secreted afterwards with a higher 60 affinity for SARS-CoV-2 (1). Typically, COVID-19 patients underwent seroconversion (from negative to positive) of IgM and IgG within 20 days (2). The IgM and IgG expression kept 61 62 elevating before reaching the plateau, with IgG plateau titers higher and longer-lasting than IgM 63 plateau titers (3). The timespans of seroreversion (from positive to negative) were around 3-6 64 months since disease onset for IgM (4, 5) whereas hardly observed for IgG in one year (6). After 65 vaccination, convalescent COVID-19 patients exhibited higher titers of IgM and IgG compared to 66 healthy individuals (7). 67 Several atypical serological patterns were documented in the literature. 3.2% to 6.9% of the 68 COVID-19 patients remained low expression or seronegative for both IgM and IgG throughout the 69 disease stage (1, 2). It has also been reported that less than 10% of the patients exhibited 10- to 20-70 fold higher antibody titers than the average values when reaching the plateau (1, 8). These 71 unexpected serological patterns indicate heterogeneous host responses during COVID-19, with 72 unclear molecular mechanisms. 73 This study was designed to investigate the diverse expression patterns of IgM and IgG from a 74 single-center cohort across two years of monitoring, and to explore the molecular evidence 75 associated with atypical antibody expression via longitudinal proteomic profiling. 76 77 **Experimental procedures** 

#### 78 Ethics and data governance approval

79 This study has been approved by the Ethical/Institutional Review Board of Westlake

80 University and Taizhou Hospital (approval notice: K20210218). The studies in this work abide by

Proteomes behind diverse COVID-19 serology

81 the Declaration of Helsinki principles. Since archived specimens were used, informed consent

82 from the patients was waived by the boards. A flowchart of the study design is illustrated in Figure

83 1D.

### **Patient information** 84

85 We included 144 COVID-19 patients who were admitted to Taizhou Public Health Medical

Center, Taizhou Hospital from January 17, 2020 to April 2, 2020. Within them, seventy-three 86

87 patients participated in the one-year follow-up between day 363-397 (IQR, 10) since disease onset

88 and fifty-eight patients participated in the two-year follow-up between day 728-763 (IQR, 7) since

89 disease onset.

90 Information about demographics, epidemiological history, clinical symptoms, laboratory

91 data, and hospitalization was collected through an electronic medical record system. All enrolled

92 patients were confirmed to be infected with SARS-CoV-2 by use of real-time reverse-transcriptase

93 polymerase-chain-reaction (RT-PCR) assay on the viral RNA extracted from nasopharyngeal or

94 sputum specimens, and the classification of their disease severity were based on Diagnostic and

95 Treatment Protocol for COVID-19 (Trial Version 5) issued by National Health Commission of the

96 People's Republic of China (9), unless otherwise mentioned. The onset date was defined as the

97 day when any symptoms were noticed by the patients.

## 98 **Removal of identifying information**

99 All information that would allow the patient/study participant or their family, friends or 100 neighbors to identify them (e.g., age, past medical history, etc.) has been removed. Patient IDs 101 from hospital records have been replaced with identifiers that cannot reveal the identity of the

102 study subjects (e.g., R001, R002, etc.). The correspondence between identifiers and patient IDs

103 was not known to anyone outside the research group.

#### 104 Laboratory characteristic tests

105 Nasopharyngeal or sputum specimens were collected to extract SARS-CoV-2 RNA, using a

- 106 nucleic acid extractor (EX3600, Shanghai Zhijiang) and a virus nucleic acid extraction kit
- 107 (P20200201, Shanghai Zhijiang). For nucleic acid detection, fluorescence quantitative PCR (ABI
- 108 7500, Thermo) coupled to a SARS- CoV-2 nucleic acid detection kit (P20200203, Shanghai

Proteomes behind diverse COVID-19 serology

109	Zhijiang) were used, which use a one-step RT-PCR combined with Taqman technology to detect					
110	RdRp, E, and N genes. "Positive" was concluded when the test for RdRp was positive (threshold					
111	cycle $<$ 43) and one of the tests for E or N was positive (threshold cycle $<$ 43), or when two					
112	sequential tests of RdRp were positive whereas the tests for E and N were negative. Other					
113	laboratory characteristic tests were conducted according to the manufacturer's protocols.					
114	Antibody analyses					
115	The IgM and IgG antibodies against SARS-CoV-2 in serum samples were measured with the					
116	chemiluminescence immunoassay (CLIA) kits (iFLASH3000, Shenzhen YHLO). CLIAs were					
117	conducted based on two-step indirect immunization according to the manufacturer's instructions.					
118	The recombinant nucleocapsid protein (N) and spike protein (S) antigens of SARS-CoV-2 were					
119	enveloped on magnetic beads, and an acridine ester labeled mouse anti-human IgM/IgG antibody					
120	was used as the detection antibody. The IgM/IgG antibody concentrations were positively					
121	correlated with the Relative Luminescence Unit (RLU). The cut-off to determine positivity was set					
122	at 10 AU/mL.					
123	The neutralizing antibodies (NAbs) against SARS-CoV-2 in serum samples were measured					
124	using CLIA kits (Caris 200, Wantai). CLIAs for neutralizing antibody detection were based on					
125	competition immunization according to the manufacturer's instructions. The neutralizing antibody					
126	in the sample and the biotinylated SARS-CoV-2 specific antibody compete with acridine ester					
127	labeled S protein. Next, streptavidin-coated magnetic particles were added. Through the					
128	interaction of biotin and streptavidin, a complex consisting of the magnetic particles coated by					
129	streptavidin, biotinylated SARS-CoV-2 specific antibody, and acridine ester S protein was formed.					
130	After washing and removing the substances that do not bind to the magnetic particles. The					
131	neutralizing antibody concentration in the sample was inversely proportional to the instrumentally					
132	detected RLU. The cut-off value to determine NAb positivity was set at 0.1 $\mu$ g/mL.					
133	Patient classification based on antibody titers					
134	The classification of COVID-19 patients was based on the maximum expression levels of					

135 IgM and IgG when reaching the plateau. The cut-off value, as determined by the detection kit, was

136 10 AU/mL. A total of 47 patients had IgM titers below the cut-off value (IgM<sup>-</sup>), and three had IgG

Proteomes behind diverse COVID-19 serology

137 titers below the cut-off value (IgG<sup>-</sup>). They were classified as seronegative for IgM and IgG,

138 respectively.

Two patients had IgG titers above but close to the cut-off value. Specifically, the IgG plateau 139 was reached on the second and the 18th day after the symptoms' onset for patients R055 (16.11 140 141 AU/mL) and R101 (13.80 AU/mL), respectively. These were the "outliers" of the patients with IgG plateau titers above the cut-off value, accordingly to Tukey's test (Figure S2A). Clinicians 142 143 classified them as seronegative for IgG (IgG<sup>-</sup>). Similarly, nine patients with very high IgM 144 expression were the "outliers" in the patients with IgM plateau titers above the cut-off value, 145 accordingly to Tukey's test. Clinicians classed them as patients with abnormally high IgM expression (IgM++). 146 147 **Proteomic analysis** 148 Serum samples were heated at 56 °C for over 60 min for inactivation. The sample preparation 149 procedures were conducted as described previously (10) with several modifications: 10  $\mu$ L serum 150 from each specimen of the sample cohort was extracted and loaded onto High Select Top14 151 Abundant Protein Depletion Mini Spin Columns (Thermo Scientific) for high abundance protein

depletion. Eluates were concentrated using Pierce<sup>TM</sup> Protein Concentrators PES, 3K MWCO 152

153 (Thermo Scientific), and denatured with 50 µL lysis buffer (6 M urea and 2 M thiourea in 0.1 M

154 triethylammonium bicarbonate, TEAB) at 31 °C for 30 min. The extracts were reduced with 10

mM tris (2-carboxyethyl) phosphine (Damas-beta) at 31°C for 40 min and alkylated with 40 mM 155

156 iodoacetamide (Sigma) at 25°C for 40 min in darkness. The samples were diluted with 0.1 M

157 TEAB buffer till the final concentration of urea was below 1.6 M, and trypsinized (Hualishi

158 Technology) in double-step with an enzyme-to-substrate ratio of 1:20 at 31°C, for 60 min and 120

159 min, respectively. Trypsinization was stopped by adding trifluoroacetic acid (Damas-beta) till the

160 final concentration of 1%, and digests were desalted with SOLAµ (Thermo Fisher Scientific),

161 following the manufacturer's instructions. Clean peptides were labeled with TMTpro 16plex label

162 reagent sets (Thermo Scientific) according to the labeling set (Figure S2). A pooled sample was

163 generated for labeling efficiency tests to ensure an incorporation ratio of over 95%. Afterward,

164 samples in the batch were combined and fractionated in previously described settings (10). 60

medRxiv preprint doi: https://doi.org/10.1101/2022.08.21.22278967; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

Proteomes behind diverse COVID-19 serology

165 fractions were derived and consolidated into 26 combined fractions. The fractions were dried and 166 re-dissolved in 30 µL 2% ACN/0.1% formic acid. For nanoLC-MS/MS analysis, an EASY-nLC<sup>™</sup> 1200 system (Thermo Fisher Scientific) coupled with Q Exactive HF-X hybrid Quadrupole-167 Orbitrap (Thermo Fisher Scientific) was applied, and data-dependent acquisition (DDA) mode 168 169 was used throughout the analysis. The parameters were as previously described (10), except a 60 min LC gradient was applied for each acquisition. The resultant data were analyzed with Proteome 170 171 Discoverer (Version 2.4.1.15). Protein database was a Homo sapiens fasta file downloaded from

172 UniprotKB on April 10, 2020 and other parameter settings were as previously described (10).

# Statistical analysis 173

174 For clinical data (demographic information and clinical indicators), p values were calculated by two-sided Wilcoxon rank-sum tests. For proteomics data, p values were calculated by one-way 175 176 analysis of variance (ANOVA) in the comparisons of divergent antibody expression and by two-177 sided Student's t-test in other analyses. Benjamini & Hochberg correction was applied for p-value adjustment and labeled as *adjusted p*. Paired analyses were applied in comparing DEPs and in the 178 179 comparisons of clinical indicators from organ dysfunction. Signs: \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p< 0.005; \*\*\*\*, p < 0.001. Spearman correlation coefficients were calculated for the correlation of 180 181 clinical data and proteomic data. LOESS (locally weighted scatterplot smoothing) model was applied for fitting analysis. Unsupervised hierarchical clustering was applied to display the DEPs 182 183 from dysregulated seroconversion.

184 Categorical variables were described as frequency and percentage, and continuous variables 185 were shown as mean and standard deviation or median and interquartile range (IQR) values as 186 appropriate. To compare the continuous variables for data from different patient groups, an independent t-test was used when the data were normally distributed; otherwise, the Kruskal-187 Wallis H test was conducted. The categorical variables were compared using the  $\chi^2$  test and 188 189 Fisher's exact test as appropriate. Statistical analyses were performed with R software (version 190 3.6.0).

## 191 **Pathway analysis**

Proteomes behind diverse COVID-19 serology

- 192 Metascape (11), String (12), and Ingenuine Pathway Analysis were applied for pathway
- 193 enrichment in this study.
- 194
- Results 195

## Negative and exceptionally high IgM and IgG expression in COVID-19 196

We procured a cohort of 144 COVID-19 patients and used chemiluminescence 197

- 198 immunoassays (CLIAs) to assess their expression levels of IgM and IgG (Methods). 790, 72, and
- 199 58 CLIA tests were conducted during the first 10 weeks since disease onset (weeks 1-10), the one-
- year revisit (R1), and the two-year revisit (R2), respectively. 84.5% of the revisited patients 200
- 201 received vaccination between R1 and R2 (Table S1). Based on their plateau titers during weeks 1-
- 202 10, the antibodies' expression patterns were classified as follows: - for negative results or very low
- expression, <sup>+</sup> for positive results, and <sup>++</sup> for exceptionally high expression (Methods). 203
- 204 Accordingly, patients were classified into four groups:  $IgG^{-}IgM^{-}$  (G<sup>-</sup>M<sup>-</sup>, N = 5),  $IgG^{+}IgM^{-}$
- $(G^+M^-, N = 42)$ , IgG<sup>+</sup>IgM<sup>+</sup> (G<sup>+</sup>M<sup>+</sup>, N = 88), and IgG<sup>+</sup>IgM<sup>++</sup> (G<sup>+</sup>M<sup>++</sup>, N = 9) (Figure S1A and 205
- 206 S1B).

We firstly assessed the IgM expression dynamics in the four groups. G<sup>+</sup>M<sup>+</sup> and G<sup>+</sup>M<sup>++</sup> 207 208 patients underwent IgM seroconversion between weeks 1-2 (Figure 1A). However, the IgM titers 209 in the G<sup>+</sup>M<sup>++</sup> group were significantly higher since week 2 and were over 20-fold in expression 210 when reaching the plateau at week 4, compared to that in the G<sup>+</sup>M<sup>+</sup> group. The IgM titers in the 211  $G^+M^+$  group remained over ten-fold higher than the  $G^+M^+$  group at weeks 7-10. Comparatively, 212 none of the patients in the G<sup>+</sup>M<sup>-</sup> or the G<sup>-</sup>M<sup>-</sup> group underwent IgM seroconversion during 213 weeks 1-10. The overall IgM titers of the four groups had a significant decrease from weeks 1-10 to R1, which were further decreased at R2. Only 13.9% (N = 10) and 5.2% (N = 3) of the revisited 214 patients were IgM seropositive at R1 and R2, respectively. The statistical differences in IgM titers 215 216 between the G<sup>+</sup>M<sup>-</sup> and the G<sup>+</sup>M<sup>+</sup> groups persisted at R1 and R2, suggesting a long-term effect of COVID-19. 217

218 As for the IgG expression dynamics, all the groups except the  $G^-M^-$  group underwent seroconversion at weeks 1-2 and reached the plateau at week 3 (Figure 1B). Their IgG titers 219

Proteomes behind diverse COVID-19 serology

220	remained at plateau levels during weeks 3-6. Thereafter, the IgG titers exhibited a mild decrease in					
221	the G <sup>+</sup> M <sup>++</sup> group at weeks 7-10. By contrast, IgG seroconversion was hardly observed in the G <sup>-</sup>					
222	M <sup>-</sup> group, and most of the IgG titers in the G <sup>-</sup> M <sup>-</sup> group were below the positivity cut-off value					
223	during weeks 1-10. The overall IgG titers in the four groups exhibited a significant decrease from					
224	weeks 1-10 to R1. Statistical differences in IgG titers between G <sup>+</sup> M <sup>-</sup> and G <sup>+</sup> M <sup>+</sup> patients were also					
225	observed at R1. The IgG expression of all of the groups was significantly enhanced from R1 to					
226	R2, which might be attributed to vaccination (Table S1).					
227						
228	Vaccination boosts IgG expression in COVID-19					
229	To evaluate the effect of vaccination on IgG expression, we classed the convalescent patients					
230	at R2 into non-vaccinated (nonVac, $N = 9$ ) and vaccinated (Vac, $N = 49$ ) groups and compared					
231	their IgG titers (Figure 1C). The Vac group exhibited significantly elevated IgG titers from R1 to					
232	R2. All of the Vac patients were seropositive at R2, including one $G^-M^-$ patient R009.					
233	Comparatively, IgG titers in the nonVac group were equivalent between R1 and R2. These					
234	observations showed that vaccination can significantly boost IgG expression for COVID-19					
235	convalescents. We also conducted 255 CLIA tests of neutralizing antibody (NAb) expression in 85					
236	patients from the cohort throughout weeks 1-10 and R1 (Table S1). The NAb titers were relatively					
237	higher in the G <sup>+</sup> M <sup>+</sup> and G <sup>+</sup> M <sup>++</sup> groups (Figure S1C) compared to others, suggestive of their					
238	stronger neutralizing abilities. NAb and IgG were positively correlated in all of the groups except					
239	for G <sup>-</sup> M <sup>-</sup> (Figure S1C), whereas NAb and IgM were not correlated (Figure S1D).					
240	Our observation showed that COVID-19 patients underwent highly diverse antibody					
241	expression, especially IgM, after viral infection. IgM turned negative while IgG persisted with a					
242	significant decrease one year after COVID-19. IgG titers were significantly boosted after					
243	vaccination.					
244						
245	COVID-19 severity and on-admission inflammation were positively correlated with antibody					
246	expression					
247	We assessed the electronic hospital records (EHRs) of the enrolled patients (Figure 2 and					

248	Table S2). None of the $G^-M^-$ patients were severe cases, whereas 34.1% of the $G^+M^+$ patients					
249	and 33.3% of the G <sup>+</sup> M <sup>++</sup> patients had severe symptoms, respectively (Figure 2A). Supportively,					
250	the G <sup>+</sup> M <sup>+</sup> and G <sup>+</sup> M <sup>++</sup> groups had significantly higher amounts of infected lung lobes and received					
251	more drug therapies, including immunoglobulin and methylprednisolone, compared to other					
252	groups (Table S2).					
253	To investigate the difference in the basic physiological status among the four groups, we					
254	compared their clinical indicators on admission (Figure 2B). Notably, risk factors such as SAA,					
255	CRP and inflammation factors such as IL-6, IL-10, and IFN- $\gamma$ , were positively correlated with					
256	IgM and IgG expression, suggesting that patients with higher antibody titers also had stronger					
257	inflammatory responses. Coagulation factor fibrinogen remained at a normal range in the G <sup>-</sup> M <sup>-</sup>					
258	group but overexpressed in some patients from the other groups, suggesting a tendency of					
259	coagulopathy in these patients. The lymphocyte amounts were negatively correlated with antibody					
260	titers and below the lower limit of normal ranges in most of the G <sup>+</sup> M <sup>++</sup> patients, suggesting that					
261	their baseline immunological status was inferior to the other patients. A series of nutritional					
262	factors such as albumin and pre-albumin, which have been reported as potential indicators for					
263	adverse outcomes in COVID-19 (13, 14), was negatively correlated with antibody expression					
264	titers.					
265	To sum up, the severity and inflammation status of COVID-19 patients on admission were					
266	positively correlated with their antibody expression titers.					
267						
268	Enhanced cellular immune responses are associated with negative IgM and IgG expression					
269	We monitored the two-year temporal changes of serum clinical indicators in our cohort					
270	(Figure 2C). In the G <sup>+</sup> M <sup>++</sup> group, the expression of CD3, CD4, and CD8, three T lymphocyte					
271	markers, was below the lower limit of the reference ranges during weeks 1-3 and was significantly					
272	lower than the other groups during weeks 1-10. CD19, a B lymphocyte marker, was lower in the					
273	G <sup>+</sup> M <sup>++</sup> group than the other groups throughout weeks 1-10 and fell below the lower limit of the					
274	reference range since week 4. Comparatively, these CD markers were highly expressed in the G <sup>-</sup>					
275	$M^-$ group until week 5. The inter-group differences of these CD markers decreased after week 7.					

Proteomes behind diverse COVID-19 serology

276	These observations suggested that the G <sup>-</sup> M <sup>-</sup> patients exhibited stronger cellular immune						
277	responses compared to the other groups. Neutrophil counts during weeks 1-4 increased in the						
278	G <sup>+</sup> M <sup>++</sup> group whereas remained equivalent in the other groups. Notably, starting from week 6,						
279	neutrophil counts in the G <sup>+</sup> M <sup>++</sup> and G <sup>+</sup> M <sup>+</sup> groups increased beyond the upper limit of the						
280	reference range. The decrease of B and T lymphocytes and the increase of neutrophils during						
281	hospitalization have been previously observed in severe (15) and deceased (16) COVID-19						
282	patients.						
283	The temporal expression of several blood lipids and lipoproteins was different between the G						
284	<sup>-</sup> M <sup>-</sup> group and the others (Figure 2C). Triglyceride (TG) increased during weeks 1-3 followed by						
285	a gradual decrease in the four groups, but only the G <sup>-</sup> M <sup>-</sup> group went back to reference ranges by						
286	week 5. The G <sup>-</sup> M <sup>-</sup> group also exhibited relatively higher expression of total cholesterol (TC),						
287	lipoprotein(a), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein						
288	cholesterol (HDL-C) during weeks 1-10. The combination of low HDL-C and high TG, termed						
289	atherogenic dyslipidemia, was considered a risk factor for severe COVID-19 (17). These						
290	observations suggest different levels of systematic dyslipidemia during COVID-19, which were						
291	the mildest in the G <sup>-</sup> M <sup>-</sup> group.						
292	Taken together, patients who remained both IgM and IgG seronegative during disease had						
293	enhanced cellular immune responses whereas less perturbation of lipid metabolism, compared to						
294	the other patients.						
295							
296	Serum proteomic investigation of four serological groups						
297	To understand the differences in host responses behind the diverse antibody expression, we						
298	collected 111 serum samples from 16 representative COVID-19 patients (Figure S2A) to profile						

299 their longitudinal proteomic signatures during weeks 1-10 (Figure 3A). A total of 1494 proteins

- 300 were characterized using TMTpro 16plex technology (Figure S2B and Table S3). The median
- 301 value of the protein coefficient of variation (CV) for the pooled samples is 0.189 (Figure S2C),

302 indicating high quality of our data.

303	To explore the proteomic differences among the four groups, ANOVA was used to assess						
304	differentially expressed proteins (DEPs) (adjusted p value < 0.05) at each week. 77 DEPs in total						
305	were identified, $61.0\%$ (n = 47) of which were from weeks 1-2 (Figure S2D). Only one of these 47						
306	proteins was overlapped with the DEPs from weeks 4-10, suggesting a distinct difference in the						
307	host responses during and after seroconversion. Accordingly, we found that the G <sup>-</sup> M <sup>-</sup> and G <sup>+</sup> M <sup>++</sup>						
308	groups could be stratified by the DEPs during weeks 1-2 but not weeks 4-10 via principal						
309	component analysis (PCA, Figure 3B).						
310	We next analyzed the key functions of the DEPs. The three most enriched pathways						
311	throughout weeks 1-10 are humoral immune responses, glycosaminoglycan binding, and						
312	carbohydrate binding (Figure 3C). Within them, humoral immune responses include multiple						
313	established risk factors of COVID-19, such as complement and fibrinogen factors (10, 18). The						
314	enrichment of Glycosaminoglycan binding might be attributed to either cytokine recognition or						
315	SARS-CoV-2 host entry (19). We then clustered the DEPs at the initial (weeks 1-2) and late						
316	(weeks 7-10) stages of COVID-19 via String (12). Complement system and prothrombin						
317	activation were the main enriched functions during weeks 1-2 (Figure 3D). Notably, the						
318	expression of C1QB and C1QC, subunits of complement 1 (C1), were significantly lower in the G						
319	<sup>-</sup> M <sup>-</sup> group compared to the G <sup>+</sup> M <sup>-</sup> and G <sup>+</sup> M <sup>+</sup> groups and further decreased in the G <sup>+</sup> M <sup>++</sup> group						
320	(Figure 3E). Comparatively, a list of downstream proteins of complement cascade, including						
321	C4BPA, C7, CFI, and CFH, were significantly upregulated in the G <sup>+</sup> M <sup>++</sup> group (Figure 3D). This						
322	observation suggested that complement system was strongly activated in the G <sup>+</sup> M <sup>++</sup> group but not						
323	via the classical C1-mediated pathway. P0DOX3, an IgD heavy chain residue, was negatively						
324	correlated with IgM expression in the four groups (Figure 3E), suggesting that IgD may						
325	compensate for the lack of IgM in the $G^-M^-$ and $G^+M^-$ groups (20). At weeks 7-10, leukocyte						
326	extravasation signaling was enriched (Figure 3F). Within them, VNN1, a proposed HDL regulator						
327	(21), was significantly upregulated in the G <sup>+</sup> M <sup>++</sup> group (Figure 3G). FCGR3A was also						
328	overexpressed in the G <sup>+</sup> M <sup>++</sup> group, which might enhance the production of pro-inflammatory						
329	cytokines and the activities of cytotoxic effector cells (22).						

Proteomes behind diverse COVID-19 serology

- 330 In summary, the proteomic differences in the four groups were the most prominent during
- 331 weeks 1-2, which were associated with complement cascades. The main host response differences

332 during the late stage of COVID-19 relate to the leukocyte activities.

333

## 334 Correlation between serum proteomes and clinical indicators

335 Beyond the functional analyses, we explored the correlation between the DEPs and the

336 antibody titers during weeks 1-4 since disease onset. Five and four DEPs were significantly

337 correlated with IgM and IgG expression titers (absolute value of Spearman correlation coefficient

338 is over 0.5), respectively (Figure 4A). Within them, TIMP1, ICAM1, CD163, NOTCH2, and

HLD-DRB1 are associated with inflammatory response, corroborating the important role of 339

340 inflammation in serology. CD163, a marker for monocytic macrophages (23), is the most

341 correlated protein with IgG among these regulators. As exemplified in Figure 4B, the expression

342 of serum CD163 was positively correlated with antibody titers and was significantly higher than

343 the other groups in the G<sup>+</sup>M<sup>+</sup> group throughout weeks 1-4, suggestive of their more activated

344 macrophage polarization during COVID-19 (24).

345 We also assessed the correlation between clinical indicators and DEPs during weeks 1-10

346 (Figure 4C). HDL-C was significantly correlated with MERTK (Figure 4D), a transmembrane

kinase that contributes to the B lymphocyte activation (25). TG was positively correlated with 347

348 serum CD34 (Figure 4E), a human hematopoietic stem cell marker that also has a role in

349 facilitating inflammatory cell trafficking. These evidences further suggested lipid involvement in

350 the immunological activities during COVID-19.

351

#### 352 A putative working model for diverse serology in COVID-19

Based on our data, we propose a putative working model regarding the diverse COVID-19 353 354 serology (Figure 4F). Complement cascade is initiated upon disease onset, mediating the secretion 355 of cytokines such as IL-6 and IL-10. This process could trigger macrophage polarization, as 356 exemplified by the upregulation of CD163, which would further modulate local inflammation. The

subsequently activated neutrophils and T lymphocytes could initiate B cell differentiation, leading 357

358	to the activation of humoral immune responses to secret antibodies. These processes might be
359	barely activated in the G <sup>-</sup> M <sup>-</sup> group due to <i>a prior</i> cellular immune responses that efficiently
360	confront the invasion of SARS-CoV-2 upon disease onset. On the contrary, the cellular immunity
361	might not be sufficient in the G <sup>+</sup> M <sup>++</sup> group for viral defense. Meanwhile, the activation of
362	complement 1 might be disturbed in the G <sup>+</sup> M <sup>++</sup> group. The high expression of inflammatory
363	factors and rapidly ascending IgM titers might be a complementary process to defend against viral
364	attacks.
365	
366	Discussion
367	In this study, we extracted two-year EHRs and applied TMTpro 16plex-based longitudinal
368	proteomics to investigate the host responses of patients with diverse serology in COVID-19. We
369	found that patients with negative IgM and IgG expression still developed strong T cell immunity
370	for viral defense, and that the overexpression of IgM was associated with perturbed complement
371	cascades and insufficient cellular immune responses.
372	Multiple studies have reported the association between antibody expression and COVID-19
373	severity. For example, Long et al. observed higher titers of IgM and IgG in severe patients than in
374	mild patients since seroconversion (1). Garcia-Beltran et al. found that severe COVID-19 patients
375	that required intubation or were passed away had the highest levels of IgG and IgA antibodies
376	compared to others (26). However, none of them have studied the mechanisms underlying the
377	differentiated antibody expression. Our manifestation that antibody expression was associated
378	with on-admission inflammatory responses supports a previous speculation that severe disease
379	might be caused by hyper-inflammation, which induces antibody overproduction (26). Conversely,
380	high antibody titers might be involved in the antibody-dependent enhancement (ADE) of viral
381	entry, which further induces the expression of inflammatory factors (27).
382	Our observation that a list of CD molecules (CD3, CD4, CD8, and CD19) were highly
383	expressed in the G <sup>-</sup> M <sup>-</sup> patients whereas decreased in the G <sup>+</sup> M <sup>++</sup> patients during COVID-19
384	suggested their differentially regulated lymphocytes to confront viral attacks. The low expression
385	of T and B lymphocyte markers, namely lymphopenia, has been established as a severity hallmark

Proteomes behind diverse COVID-19 serology

386	in previous studies (15, 28), further supporting our data. Notably, intra-group differences of these					
387	molecules were not as significant after week 5, which might result from medical treatment (29).					
388	Therefore, the evaluation of lymphopenia on COVID-19 severity is recommended within one					
389	month since disease onset. Comparatively, CD163 as shown in our serum proteomics data was					
390	continuously upregulated during seroconversion in the G <sup>+</sup> M <sup>++</sup> group. The high expression of					
391	CD163 has also been detected in the autopsy samples of six organs in the deceased COVID-19					
392	patients (30), the peripheral blood mononuclear cells during COVID-19, and the THP-1 cell line					
393	after 48 hours of SARS-CoV-2 infection (24). A recent study reported that an overexpression of					
394	pulmonary CD163 might lead to idiopathic pulmonary fibrosis in COVID-19 (31). These					
395	observations collectively suggest that overly activated macrophage functions might not be					
396	favorable to COVID-19 recovery.					
397	Although lipid metabolism dysregulation is typical in COVID-19 (10), our data showed that					
398	seronegative patients had the mildest symptoms of dyslipidemia compared to others. This might					
399	be attributed to their relatively milder inflammation, which mediates cytokine secretion that alters					
400	lipid homeostasis (32). We also found clues that HDL-C and TG might be associated with					
401	leukocyte activation during COVID-19. Mechanistic studies are needed in the future to explore					
402	their causality.					
403	Our observation that SARS-CoV-2-specific IgG declined significantly one year after					
404	COVID-19 was in line with previous reports (33), suggesting a transition into immune memories.					
405	This also underlined the necessity of vaccinating recovered populations, which could significantly					
406	enhance IgG titers two years after COVID-19, according to our data. Notably, $85.7\%$ (N = 42) of					
407	the vaccinated patients in our cohort received at least two doses of inactivated vaccines as of R2.					
408	Previous studies have shown that one to two doses of adenoviral vector or mRNA vaccines, were					
409	also viable to boost IgG and NAb titers in the recovered patients (7, 34). A longer-term serological					
410	monitoring of the same cohort is expected to understand the long-term humoral immunity in the					
411	vaccinated population with previous SARS-CoV-2 infection.					
412	Our study has several limitations. Firstly, the single-center study with a relatively small					

413 patient cohort was possibly subject to demographic and experimental biases. Also, the sampling

Proteomes behind diverse COVID-19 serology

- 414 time points failed to cover the seroreversion stages for IgG. Furthermore, as the major purpose is
- 415 to profile host responses associated with diverse serology patterns, we didn't validate specific
- 416 markers in this study.
- 417

## Data availability 418

- Patient information and serology data are available in the supplementary material. The 419
- 420 proteomic raw data are deposited in ProteomeXchange Consortium
- 421 (https://www.iprox.cn/page/PSV023.html;?url=1660551727880pH06, password: VcQ7).
- 422

# 423 Acknowledgments

- 424 This work was supported by grants from National Key R&D Program of China
- 425 (2021YFA1301602, 2020YFE0202200), National Natural Science Foundation of China
- 426 (81972492, 21904107, 82072333), Zhejiang Provincial Natural Science Foundation for
- Distinguished Young Scholars (LR19C050001), Hangzhou Agriculture and Society Advancement 427
- 428 Program (20190101A04), Medical Science and Technology Project of Zhejiang Province
- (2021KY394), Westlake Education Foundation, and Scientific Research Foundation of Taizhou 429
- 430 Enze Medical Center (Group) (21EZZX01). We thank Westlake University Supercomputer Center
- 431 for assistance in data storage and computation.
- 432

## 433 **Author Contributions**

- Y.Z., B.S., and T.G. designed the project, Y.Z., J.W., K.Z., D.W., and G.Z. collected the samples, 434
- 435 X.L., J.W., K.Z., J.L, S.C., M.L., J.P., J.X., H.Z., and G.Z. organized the sample information, X.L.,
- S.L., and X.Y. prepared the samples, X.L., M.L., Y.S., Y.X., and Q.Z. performed the data analysis, 436
- X.L., Y.X., and Q.Z. designed the figures, X.L. and R.S. wrote the manuscript, Y.Z., B.S., Y.Z., 437
- 438 and T.G. supervised the project.
- 439

## **Competing Interests statement** 440

Q.Z. and X.Y. are employees of Westlake Omics Inc. Y.Z. and T.G. are shareholders of Westlake 441

Proteomes behind diverse COVID-19 serology

442 Omics Inc. The remaining authors declare no competing interests.

443

# 444 Supplementary data

This article contains supplemental material Table S1-S3 and Figure S1-S2. 445

446

447

Proteomes behind diverse COVID-19 serology

#### 448 References

- 449 1. Long, Q. X., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., Liao, P., Qiu, J. F., Lin, Y.,
- 450 Cai, X. F., Wang, D. Q., Hu, Y., Ren, J. H., Tang, N., Xu, Y. Y., Yu, L. H., Mo, Z., Gong, F., Zhang, X.
- 451 L., Tian, W. G., Hu, L., Zhang, X. X., Xiang, J. L., Du, H. X., Liu, H. W., Lang, C. H., Luo, X. H., Wu, S.
- 452 B., Cui, X. P., Zhou, Z., Zhu, M. M., Wang, J., Xue, C. J., Li, X. F., Wang, L., Li, Z. J., Wang, K., Niu, C.
- 453 C., Yang, Q. J., Tang, X. J., Zhang, Y., Liu, X. M., Li, J. J., Zhang, D. C., Zhang, F., Liu, P., Yuan, J., Li,
- 454 Q., Hu, J. L., Chen, J., and Huang, A. L. (2020) Antibody responses to SARS-CoV-2 in patients
- 455 with COVID-19. Nat Med 26, 845-848
- 456 2. Zhao, J., Yuan, O., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., Oian, S.,
- 457 Hong, C., Wang, F., Liu, Y., Wang, Z., He, Q., Li, Z., He, B., Zhang, T., Fu, Y., Ge, S., Liu, L., Zhang, J.,
- 458 Xia, N., and Zhang, Z. (2020) Antibody Responses to SARS-CoV-2 in Patients With Novel
- 459 Coronavirus Disease 2019. Clin Infect Dis 71, 2027-2034
- 460 Jin, Y., Wang, M., Zuo, Z., Fan, C., Ye, F., Cai, Z., Wang, Y., Cui, H., Pan, K., and Xu, A. (2020) 3.
- 461 Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.
- 462 International Journal of Infectious Diseases 94, 49-52
- 463 lyer, A. S., Jones, F. K., Nodoushani, A., Kelly, M., Becker, M., Slater, D., Mills, R., Teng, E., 4.
- 464 Kamruzzaman, M., Garcia-Beltran, W. F., Astudillo, M., Yang, D., Miller, T. E., Oliver, E., Fischinger,
- 465 S., Atyeo, C., Iafrate, A. J., Calderwood, S. B., Lauer, S. A., Yu, J., Li, Z., Feldman, J., Hauser, B. M.,
- 466 Caradonna, T. M., Branda, J. A., Turbett, S. E., LaRocque, R. C., Mellon, G., Barouch, D. H.,
- 467 Schmidt, A. G., Azman, A. S., Alter, G., Ryan, E. T., Harris, J. B., and Charles, R. C. (2020)
- 468 Persistence and decay of human antibody responses to the receptor binding domain of SARS-
- 469 CoV-2 spike protein in COVID-19 patients. Sci Immunol 5, eabe0367
- 470 5. den Hartog, G., Vos, E. R. A., van den Hoogen, L. L., van Boven, M., Schepp, R. M., Smits, G.,
- 471 van Vliet, J., Woudstra, L., Wijmenga-Monsuur, A. J., van Hagen, C. C. E., Sanders, E. A. M., de
- 472 Melker, H. E., van der Klis, F. R. M., and van Binnendijk, R. S. (2021) Persistence of Antibodies to
- 473 Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide
- 474 Prospective Study. Clin Infect Dis 73, 2155-2162
- 475 Masiá, M., Fernández-González, M., Telenti, G., Agulló, V., García, J. A., Padilla, S., García-6.

ade available under a CC-DT-NC-ND 4.0 International licen

- 476 Abellán, J., Galiana, A., Gonzalo-Jiménez, N., and Gutiérrez, F. (2021) Durable antibody response
- 477 one year after hospitalization for COVID-19: A longitudinal cohort study. *J Autoimmun* 123,
- 478 102703-102703
- 479 7. Ali, H., Alahmad, B., Al-Shammari, A. A., Alterki, A., Hammad, M., Cherian, P., Alkhairi, I.,
- 480 Sindhu, S., Thanaraj, T. A., Mohammad, A., Alghanim, G., Deverajan, S., Ahmad, R., El-Shazly, S.,
- 481 Dashti, A. A., Shehab, M., Al-Sabah, S., Alkandari, A., Abubaker, J., Abu-Farha, M., and Al-Mulla,
- 482 F. (2021) Previous COVID-19 Infection and Antibody Levels After Vaccination. *Frontiers in public*
- 483 *health* 9, 778243-778243
- 484 8. Geyer, P. E., Arend, F. M., Doll, S., Louiset, M.-L., Virreira Winter, S., Müller-Reif, J. B., Torun,
- 485 F. M., Weigand, M., Eichhorn, P., Bruegel, M., Strauss, M. T., Holdt, L. M., Mann, M., and Teupser,
- 486 D. (2021) High-resolution serum proteome trajectories in COVID-19 reveal patient-specific
- 487 seroconversion. EMBO Mol Med 13, e14167-e14167
- 488 9. Suhre, K., McCarthy, M. I., and Schwenk, J. M. (2020) Genetics meets proteomics:
- 489 perspectives for large population based studies. *Nat Rev Genet*
- 490 10. Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., Ge, W.,
- 491 Liu, W., Liang, S., Chen, H., Zhang, Y., Li, J., Xu, J., He, Z., Chen, B., Wang, J., Yan, H., Zheng, Y.,
- 492 Wang, D., Zhu, J., Kong, Z., Kang, Z., Liang, X., Ding, X., Ruan, G., Xiang, N., Cai, X., Gao, H., Li, L.,
- Li, S., Xiao, Q., Lu, T., Zhu, Y., Liu, H., Chen, H., and Guo, T. (2020) Proteomic and Metabolomic
- 494 Characterization of COVID-19 Patient Sera. *Cell* 182, 59-72.e15
- 495 11. Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C.,
- 496 and Chanda, S. K. (2019) Metascape provides a biologist-oriented resource for the analysis of
- 497 systems-level datasets. *Nat Commun* 10, 1523
- 498 12. Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M.,
- 499 Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J., and Mering, C. V. (2019) STRING v11:
- 500 protein-protein association networks with increased coverage, supporting functional discovery in
- 501 genome-wide experimental datasets. Nucleic Acids Res 47, D607-d613
- 502 13. Aziz, M., Fatima, R., Lee-Smith, W., and Assaly, R. (2020) The association of low serum
- albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care 24, 255

lade available under a CC-BY-INC-IND 4.0 International licen

- 504 14. Luo, Y., Xue, Y., Mao, L., Yuan, X., Lin, Q., Tang, G., Song, H., Wang, F., and Sun, Z. (2020)
- 505 Prealbumin as a Predictor of Prognosis in Patients With Coronavirus Disease 2019. *Front Med*506 (*Lausanne*) 7, 374
- 507 15. Akbari, H., Tabrizi, R., Lankarani, K. B., Aria, H., Vakili, S., Asadian, F., Noroozi, S., Keshavarz,
- 508 P., and Faramarz, S. (2020) The role of cytokine profile and lymphocyte subsets in the severity of
- 509 coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *Life Sci* 258,
- 510 118167
- 511 16. Zhao, Y., Nie, H. X., Hu, K., Wu, X. J., Zhang, Y. T., Wang, M. M., Wang, T., Zheng, Z. S., Li, X.
- 512 C., and Zeng, S. L. (2020) Abnormal immunity of non-survivors with COVID-19: predictors for
- 513 mortality. *Infect Dis Poverty* 9, 108
- 514 17. Masana, L., Correig, E., Ibarretxe, D., Anoro, E., Arroyo, J. A., Jericó, C., Guerrero, C., Miret,
- 515 M., Näf, S., Pardo, A., Perea, V., Pérez-Bernalte, R., Plana, N., Ramírez-Montesinos, R., Royuela,
- 516 M., Soler, C., Urquizu-Padilla, M., Zamora, A., and Pedro-Botet, J. (2021) Low HDL and high
- 517 triglycerides predict COVID-19 severity. *Sci Rep* 11, 7217
- 518 18. D'Alessandro, A., Thomas, T., Dzieciatkowska, M., Hill, R. C., Francis, R. O., Hudson, K. E.,
- 519 Zimring, J. C., Hod, E. A., Spitalnik, S. L., and Hansen, K. C. (2020) Serum Proteomics in COVID-19
- 520 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level. Journal of
- 521 *proteome research* 19, 4417-4427
- 522 19. Schneider, W. M., Luna, J. M., Hoffmann, H. H., Sánchez-Rivera, F. J., Leal, A. A., Ashbrook, A.
- 523 W., Le Pen, J., Ricardo-Lax, I., Michailidis, E., Peace, A., Stenzel, A. F., Lowe, S. W., MacDonald, M.
- 524 R., Rice, C. M., and Poirier, J. T. (2021) Genome-Scale Identification of SARS-CoV-2 and Pan-
- 525 coronavirus Host Factor Networks. *Cell* 184, 120-132.e114
- 526 20. Lutz, C., Ledermann, B., Kosco-Vilbois, M. H., Ochsenbein, A. F., Zinkernagel, R. M., Köhler,
- 527 G., and Brombacher, F. (1998) IgD can largely substitute for loss of IgM function in B cells. *Nature*
- 528 393, 797-801
- 529 21. Holleboom, A. G., Vergeer, M., Hovingh, G. K., Kastelein, J. J., and Kuivenhoven, J. A. (2008)
- 530 The value of HDL genetics. *Current opinion in lipidology* 19, 385-394
- 531 22. Chakraborty, S., Gonzalez, J., Edwards, K., Mallajosyula, V., Buzzanco, A. S., Sherwood, R.,

- 532 Buffone, C., Kathale, N., Providenza, S., Xie, M. M., Andrews, J. R., Blish, C. A., Singh, U., Dugan, H.,
- 533 Wilson, P. C., Pham, T. D., Boyd, S. D., Nadeau, K. C., Pinsky, B. A., Zhang, S., Memoli, M. J.,
- 534 Taubenberger, J. K., Morales, T., Schapiro, J. M., Tan, G. S., Jagannathan, P., and Wang, T. T.
- 535 (2021) Proinflammatory IgG Fc structures in patients with severe COVID-19. Nature immunology
- 536 22, 67-73
- 537 23. Etzerodt, A., and Moestrup, S. K. (2013) CD163 and inflammation: biological, diagnostic, and
  538 therapeutic aspects. *Antioxid Redox Signal* 18, 2352-2363
- 539 24. Boumaza, A., Gay, L., Mezouar, S., Bestion, E., Diallo, A. B., Michel, M., Desnues, B., Raoult,
- 540 D., La Scola, B., Halfon, P., Vitte, J., Olive, D., and Mege, J. L. (2021) Monocytes and Macrophages,
- 541 Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease
- 542 2019 Immunoparalysis. J Infect Dis 224, 395-406
- 543 25. Shao, W. H., Zhen, Y., Finkelman, F. D., and Cohen, P. L. (2014) The Mertk receptor tyrosine
- kinase promotes T-B interaction stimulated by IgD B-cell receptor cross-linking. *J Autoimmun*53, 78-84
- 546 26. Garcia-Beltran, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J., Hauser,
- 547 B. M., Caradonna, T. M., Clayton, K. L., Nitido, A. D., Murali, M. R., Alter, G., Charles, R. C., Dighe,
- 548 A., Branda, J. A., Lennerz, J. K., Lingwood, D., Schmidt, A. G., lafrate, A. J., and Balazs, A. B. (2021)
- 549 COVID-19-neutralizing antibodies predict disease severity and survival. *Cell* 184, 476-488.e411
- 550 27. Wen, J., Cheng, Y., Ling, R., Dai, Y., Huang, B., Huang, W., Zhang, S., and Jiang, Y. (2020)
- 551 Antibody-dependent enhancement of coronavirus. Int J Infect Dis 100, 483-489
- 552 28. Liu, K., Yang, T., Peng, X. F., Lv, S. M., Ye, X. L., Zhao, T. S., Li, J. C., Shao, Z. J., Lu, Q. B., Li, J.
- 553 Y., and Liu, W. (2021) A systematic meta-analysis of immune signatures in patients with COVID-
- 554 19. *Rev Med Virol* 31, e2195
- 555 29. He, R., Lu, Z., Zhang, L., Fan, T., Xiong, R., Shen, X., Feng, H., Meng, H., Lin, W., Jiang, W., and
- 556 Geng, Q. (2020) The clinical course and its correlated immune status in COVID-19 pneumonia. J
- 557 *Clin Virol* 127, 104361
- 558 30. Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., Li,
- 559 X., Sun, Y., Li, L., Xu, L., Li, Y., Yang, M., Xue, Z., Liang, S., Ding, X., Yuan, C., Peng, L., Liu, W., Yi, X.,

Proteomes behind diverse COVID-19 serology

- 560 Lyu, M., Xiao, G., Xu, X., Ge, W., He, J., Fan, J., Wu, J., Luo, M., Chang, X., Pan, H., Cai, X., Zhou, J.,
- 561 Yu, J., Gao, H., Xie, M., Wang, S., Ruan, G., Chen, H., Su, H., Mei, H., Luo, D., Zhao, D., Xu, F., Li, Y.,
- 562 Zhu, Y., Xia, J., Hu, Y., and Guo, T. (2021) Multi-organ proteomic landscape of COVID-19
- 563 autopsies. *Cell* 184, 775-791.e714
- 564 31. Wendisch, D., Dietrich, O., Mari, T., von Stillfried, S., Ibarra, I. L., Mittermaier, M., Mache, C.,
- 565 Chua, R. L., Knoll, R., Timm, S., Brumhard, S., Krammer, T., Zauber, H., Hiller, A. L., Pascual-
- Reguant, A., Mothes, R., Bülow, R. D., Schulze, J., Leipold, A. M., Djudjaj, S., Erhard, F., Geffers, R.,
- 567 Pott, F., Kazmierski, J., Radke, J., Pergantis, P., Baßler, K., Conrad, C., Aschenbrenner, A. C.,
- 568 Sawitzki, B., Landthaler, M., Wyler, E., Horst, D., Hippenstiel, S., Hocke, A., Heppner, F. L., Uhrig,
- A., Garcia, C., Machleidt, F., Herold, S., Elezkurtaj, S., Thibeault, C., Witzenrath, M., Cochain, C.,
- 570 Suttorp, N., Drosten, C., Goffinet, C., Kurth, F., Schultze, J. L., Radbruch, H., Ochs, M., Eils, R.,
- 571 Müller-Redetzky, H., Hauser, A. E., Luecken, M. D., Theis, F. J., Conrad, C., Wolff, T., Boor, P.,
- 572 Selbach, M., Saliba, A. E., and Sander, L. E. (2021) SARS-CoV-2 infection triggers profibrotic
- 573 macrophage responses and lung fibrosis. *Cell* 184, 6243-6261.e6227
- 574 32. Li, Y., Zhang, Y., Lu, R., Dai, M., Shen, M., Zhang, J., Cui, Y., Liu, B., Lin, F., Chen, L., Han, D.,
- 575 Fan, Y., Zeng, Y., Li, W., Li, S., Chen, X., Li, H., and Pan, P. (2021) Lipid metabolism changes in
- patients with severe COVID-19. *Clin Chim Acta* 517, 66-73
- 577 33. Zhang, J., Lin, H., Ye, B., Zhao, M., Zhan, J., Dong, S., Guo, Y., Zhao, Y., Li, M., Liu, S., Zhang,
- 578 H., Xiao, W., Guo, Y., Yue, C., Zhang, D., Yang, M., Zhang, J., Quan, C., Shi, W., Liu, X., Liu, P.,
- Jiang, Y., Wu, G., Gao, G. F., and Liu, W. J. (2021) One-year sustained cellular and humoral
- 580 immunities of COVID-19 convalescents. *Clin Infect Dis*
- 581 34. Favresse, J., Gillot, C., Di Chiaro, L., Eucher, C., Elsen, M., Van Eeckhoudt, S., David, C.,
- 582 Morimont, L., Dogné, J. M., and Douxfils, J. (2021) Neutralizing Antibodies in COVID-19 Patients
- and Vaccine Recipients after Two Doses of BNT162b2. *Viruses* 13
- 584

585

Proteomes behind diverse COVID-19 serology

### 586 **Figure legends**

- 587 Figure 1 Overview of antibody expression in COVID-19. A-B) Classification and Two-year
- 588 monitoring of SARS-CoV-2-specific IgM and IgG expression in COVID-19 patients. The y-axis
- 589 denotes log-transformed antibody titers. The statistical significance was calculated within and
- 590 across each timepoint. C) Comparison of IgG expression before and after vaccination. D) Study
- 591 design for clinical and proteomic analyses of diverse serology in COVID-19.
- 592
- 593 Figure 2 Clinical characteristics of patients with diverse serology. A) Distributions of severe
- 594 cases in the four groups. B) Expression of nine selected clinical indicators on admission. C) Two-
- 595 year temporal expression of ten selected clinical indicators.
- 596


#### 597 Figure 3 Longitudinal serum proteomics of 16 characteristic patients with diverse serology.

- 598 A) Temporal serum sampling for the 16 characteristic patients. B) Heatmap and functional
- 599 annotation of 77 DEPs across 10 weeks of proteomic profiling. C) PCA of serum samples
- 600 stratified by the DEPs at weeks 1-2 and weeks 4-10, respectively. The ellipses are shown at a
- 601 confidence interval of 95%. D) Interaction network of selected DEPs at weeks 1-2. E) Relative
- 602 expression of DEPs C1QB, C1QC, and IgD at weeks 1-2. F) Interaction network of selected DEPs
- 603 at weeks 7-10. G) Relative expression of DEPs VNN1 and FCGR3A at weeks 7-10.
- 604

605	Figure 4	Correlations o	f DEPs with	ı antibody ar	nd clinical ir	ndicators ex	pression. A	) Nine


- 606 DEPs that were correlated with antibody expression during weeks 1-4 (absolute values of
- 607 spearman correlation > 0.5). B) Temporal expression of CD163 during weeks 1-4. C)
- 608 Correlations of clinical indicators with DEPs during weeks 1-10 (absolute values of spearman
- 609 correlation > 0.65). D-E) Scatterplots of two sets of correlations: MERTK~HDL-C and
- 610 CD34~TG, respectively. F) A putative working model for the host responses behind diverse
- 611 COVID-19 serology.


# Figure 1




С

# Figure 2













Figure 4



Plasma cell